AEZS : Aeterna Zentaris Inc Stock Profile

Last Updated: 3/12/2024 0:47:16

Aeterna Zentaris Inc trades with the ticker AEZS on the TSX and is in the Biotechnology industry.

Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications; and AEZS-150, a delayed clearance parathyroid hormonefusion polypeptide that is in preclinical trail for the treatment of hypoparathyroidism in adults. Aeterna Zentaris Inc. has a license agreement with University of Wuerzburg to research, develop, manufacture, and sell a potential COVID-19 vaccine; development, manufacture, and commercialization of the treatment for neuromyelitis optica spectrum disorder; and for pre-clinical development towards the potential treatment of Parkinson’s disease. It also has a license agreement with Consilient Health Ltd. and NK MEDITECH Ltd. for the development and commercialization of macimorelin in the Republic of Korea; a distribution and commercialization agreement with Er-Kim Pharmaceuticals Bulgaria EOOD for the commercialization of macimorelin for the diagnosis of growth hormone deficiency in children and adults in Turkey and some non-European Union Balkan countries; as well as The University of Sheffield, the United Kingdom for the research, development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of primary hypoparathyroidism. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Summerville, South Carolina.

Looking to invest in Aeterna Zentaris Inc? Our analysis brings in the key facts, competitor research and valuation metrics for you to make an informed decision.

AEZS.TO Stock Price and Key Stats

ETF Key Stats

Exchange: TSX

Market Cap : $12.674MM

PE Ratio:

Price: 1.88 (Updated: 3/12/2024 0:47:16)

Aeterna Zentaris Inc (AEZS) vs Competitors in Biotechnology

Lets see how AEZS.TO stacks up against others in the Biotechnology asset management industry. We have identified its main peers as:

Aptose Biosciences Inc, BELLUS Health Inc, Fennec Pharmaceuticals Inc, IMV Inc, Intellipharmaceutics International Inc


Biotechnology Industry Comparisons

Company Market Cap ($MM) P/E Ratio EV/EBITDA Dividend Yield
Aeterna Zentaris Inc (AEZS) $12.674 N/A 1.709 N/A%
Aptose Biosciences Inc (APS) $33.927 N/A -0.231 N/A%
BELLUS Health Inc (BLU) $2,470.298 N/A -16.428 0.0%
Fennec Pharmaceuticals Inc (FRX) $352.565 N/A -21.793 N/A%
IMV Inc (IMV) $13.117 N/A -0.843 0.0%

EV/EBITDA: Enterprise Value to Earnings Before Interest, Taxes, Depreciation, and Amortization – this ratio compares the value of a company, including debt, to the company’s cash earnings less non-cash expenses
Industry: companies that have a lot in common
Market Cap: Market Capitalization – the total value of all a corporation’s stock
N/A: Not Applicable or Not Available
P/E: Price-to-Earnings – this ratio relates a corporation’s share price to its earnings per share
Price: Stock Price – current value to buyers and sellers
Dividend Yield: Dividend or Distribution Yield  

Comparisons within Biotechnology

  • Aeterna Zentaris Inc (AEZS) vs Aptose Biosciences Inc (APS)
    • AEZS has higher EPS (-6.47 vs -10.45). APS and AEZS both have P/E’s under 0.
  • Aeterna Zentaris Inc (AEZS) vs BELLUS Health Inc (BLU)
    • BLU has higher EPS (-0.96 vs -6.47). BLU provides dividends, while AEZS does not. BLU and AEZS both have P/E’s under 0.
  • Aeterna Zentaris Inc (AEZS) vs Fennec Pharmaceuticals Inc (FRX)
    • FRX has higher EPS (-1.01 vs -6.47). FRX and AEZS both have P/E’s under 0.
  • Aeterna Zentaris Inc (AEZS) vs IMV Inc (IMV)
    • IMV has higher EPS (-6.11 vs -6.47). IMV provides dividends, while AEZS does not. IMV and AEZS both have P/E’s under 0.
  • Aeterna Zentaris Inc (AEZS) vs Intellipharmaceutics International Inc (IPCI)
    • IPCI has higher EPS (-0.12 vs -6.47). IPCI and AEZS both have P/E’s under 0.

Our Recommendation: Review
May not stand out on key metrics or lacks sufficient data for a strong recommendation.

How to Buy AEZS stock on the TSX

You can buy on pretty much any online brokerage in Canada, since it trades on the TSX. If you are looking for some easy options take a look at these two:

ImageProduct TitleFeaturesPrice
Editor's Choice
Wealthsimple Trade

Wealthsimple Trade

  • ETF buys and sells have $0 trading fees
  • Desktop and mobile trading
  • Reputable Brand
  • Beautiful Design
Get $25 Signup Bonus
Reliable Pick


  • ETF buys have $0 trading fees
  • Desktop and mobile trading
  • Most types of accounts available
Get $50 Free Stock Trades
Photo of author
Author Bio - Qayyum Rajan is a CFA Charterholder with 10+ years of finance experience and the co-creator of He has previously worked as a portfolio manager at RBC Dominion Securities and other roles at asset managers like Sentry Investments. He then started building websites and fintech apps to bring finance to everyone.

Check Out These Posts:

Leave a Comment